APA (7th ed.) Citation

Dimopoulos, M. A., & Goldschmidt, H. (2017). Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial. The lancet. Oncology, 18(10), . https://doi.org/10.1016/S1470-2045(17)30578-8

Chicago Style (17th ed.) Citation

Dimopoulos, Meletios A., and Hartmut Goldschmidt. "Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open-label, Randomised, Phase 3 Trial." The Lancet. Oncology 18, no. 10 (2017). https://doi.org/10.1016/S1470-2045(17)30578-8.

MLA (9th ed.) Citation

Dimopoulos, Meletios A., and Hartmut Goldschmidt. "Carfilzomib or Bortezomib in Relapsed or Refractory Multiple Myeloma (ENDEAVOR): An Interim Overall Survival Analysis of an Open-label, Randomised, Phase 3 Trial." The Lancet. Oncology, vol. 18, no. 10, 2017, https://doi.org/10.1016/S1470-2045(17)30578-8.